Anti Ageing Drugs Market

ID: MRFR/Pharma/2408-CR
260 Pages
Satyendra Maurya
Last Updated: June 24, 2026
Anti-Ageing Drugs Market Research Report Information by Drug Class (Serums and Supplements, Antioxidants and Enzymes, Stem Cells, and Drugs), by Application (Skin and Hair, Skeletal and Muscles, Age Related Disorders, and Others) by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2035
Anti Ageing Drugs Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.92%
2024 Market Size$ 47.9 Billion
2025 Market Size$ 51.21 Billion
2035 Market Size$ 100 Billion
Key Players
Companies such as Allergan
Galderma
Revance Therapeutics
Medytox
Hugel
Ipsen
Opportunities
  • Increasing Aging Population
  • Rising Health Consciousness
  • Advancements in Biotechnology
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Drug Class (USD Billion) | |
      1. 4.1.1 Serums And Supplements | |
      2. 4.1.2 Antioxidants And Enzymes | |
      3. 4.1.3 Stem Cells | |
      4. 4.1.4 Drugs |
    2. 4.2 Healthcare, BY Application (USD Billion) | |
      1. 4.2.1 Skin And Hair | |
      2. 4.2.2 Skeletal And Muscles | |
      3. 4.2.3 Age Related Disorders | |
      4. 4.2.4 Others |
    3. 4.3 Healthcare, BY Region (USD Billion) | |
      1. 4.3.1 North America | | |
        1. 4.3.1.1 US | | |
        2. 4.3.1.2 Canada | |
      2. 4.3.2 Europe | | |
        1. 4.3.2.1 Germany | | |
        2. 4.3.2.2 UK | | |
        3. 4.3.2.3 France | | |
        4. 4.3.2.4 Russia | | |
        5. 4.3.2.5 Italy | | |
        6. 4.3.2.6 Spain | | |
        7. 4.3.2.7 Rest of Europe | |
      3. 4.3.3 APAC | | |
        1. 4.3.3.1 China | | |
        2. 4.3.3.2 India | | |
        3. 4.3.3.3 Japan | | |
        4. 4.3.3.4 South Korea | | |
        5. 4.3.3.5 Malaysia | | |
        6. 4.3.3.6 Thailand | | |
        7. 4.3.3.7 Indonesia | | |
        8. 4.3.3.8 Rest of APAC | |
      4. 4.3.4 South America | | |
        1. 4.3.4.1 Brazil | | |
        2. 4.3.4.2 Mexico | | |
        3. 4.3.4.3 Argentina | | |
        4. 4.3.4.4 Rest of South America | |
      5. 4.3.5 MEA | | |
        1. 4.3.5.1 GCC Countries | | |
        2. 4.3.5.2 South Africa | | |
        3. 4.3.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Allergan (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Galderma (CH) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Revance Therapeutics (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Medytox (KR) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Hugel (KR) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Ipsen (FR) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Sientra (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Medytox (KR) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY DRUG CLASS |
    7. 6.4 US MARKET ANALYSIS BY APPLICATION |
    8. 6.5 CANADA MARKET ANALYSIS BY DRUG CLASS |
    9. 6.6 CANADA MARKET ANALYSIS BY APPLICATION |
    10. 6.7 EUROPE MARKET ANALYSIS |
    11. 6.8 GERMANY MARKET ANALYSIS BY DRUG CLASS |
    12. 6.9 GERMANY MARKET ANALYSIS BY APPLICATION |
    13. 6.10 UK MARKET ANALYSIS BY DRUG CLASS |
    14. 6.11 UK MARKET ANALYSIS BY APPLICATION |
    15. 6.12 FRANCE MARKET ANALYSIS BY DRUG CLASS |
    16. 6.13 FRANCE MARKET ANALYSIS BY APPLICATION |
    17. 6.14 RUSSIA MARKET ANALYSIS BY DRUG CLASS |
    18. 6.15 RUSSIA MARKET ANALYSIS BY APPLICATION |
    19. 6.16 ITALY MARKET ANALYSIS BY DRUG CLASS |
    20. 6.17 ITALY MARKET ANALYSIS BY APPLICATION |
    21. 6.18 SPAIN MARKET ANALYSIS BY DRUG CLASS |
    22. 6.19 SPAIN MARKET ANALYSIS BY APPLICATION |
    23. 6.20 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS |
    24. 6.21 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
    25. 6.22 APAC MARKET ANALYSIS |
    26. 6.23 CHINA MARKET ANALYSIS BY DRUG CLASS |
    27. 6.24 CHINA MARKET ANALYSIS BY APPLICATION |
    28. 6.25 INDIA MARKET ANALYSIS BY DRUG CLASS |
    29. 6.26 INDIA MARKET ANALYSIS BY APPLICATION |
    30. 6.27 JAPAN MARKET ANALYSIS BY DRUG CLASS |
    31. 6.28 JAPAN MARKET ANALYSIS BY APPLICATION |
    32. 6.29 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS |
    33. 6.30 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
    34. 6.31 MALAYSIA MARKET ANALYSIS BY DRUG CLASS |
    35. 6.32 MALAYSIA MARKET ANALYSIS BY APPLICATION |
    36. 6.33 THAILAND MARKET ANALYSIS BY DRUG CLASS |
    37. 6.34 THAILAND MARKET ANALYSIS BY APPLICATION |
    38. 6.35 INDONESIA MARKET ANALYSIS BY DRUG CLASS |
    39. 6.36 INDONESIA MARKET ANALYSIS BY APPLICATION |
    40. 6.37 REST OF APAC MARKET ANALYSIS BY DRUG CLASS |
    41. 6.38 REST OF APAC MARKET ANALYSIS BY APPLICATION |
    42. 6.39 SOUTH AMERICA MARKET ANALYSIS |
    43. 6.40 BRAZIL MARKET ANALYSIS BY DRUG CLASS |
    44. 6.41 BRAZIL MARKET ANALYSIS BY APPLICATION |
    45. 6.42 MEXICO MARKET ANALYSIS BY DRUG CLASS |
    46. 6.43 MEXICO MARKET ANALYSIS BY APPLICATION |
    47. 6.44 ARGENTINA MARKET ANALYSIS BY DRUG CLASS |
    48. 6.45 ARGENTINA MARKET ANALYSIS BY APPLICATION |
    49. 6.46 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS |
    50. 6.47 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
    51. 6.48 MEA MARKET ANALYSIS |
    52. 6.49 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS |
    53. 6.50 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
    54. 6.51 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS |
    55. 6.52 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
    56. 6.53 REST OF MEA MARKET ANALYSIS BY DRUG CLASS |
    57. 6.54 REST OF MEA MARKET ANALYSIS BY APPLICATION |
    58. 6.55 KEY BUYING CRITERIA OF HEALTHCARE |
    59. 6.56 RESEARCH PROCESS OF MRFR |
    60. 6.57 DRO ANALYSIS OF HEALTHCARE |
    61. 6.58 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    62. 6.59 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    63. 6.60 SUPPLY / VALUE CHAIN: HEALTHCARE |
    64. 6.61 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE) |
    65. 6.62 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion) |
    66. 6.63 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
    67. 6.64 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
    68. 6.65 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    69. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    70. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion) |
    71. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY APPLICATION, 2025-2035 (USD Billion) |
    72. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY APPLICATION, 2025-2035 (USD Billion) |
    73. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY APPLICATION, 2025-2035 (USD Billion) |
    74. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY APPLICATION, 2025-2035 (USD Billion) |
    75. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY APPLICATION, 2025-2035 (USD Billion) |
    76. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY APPLICATION, 2025-2035 (USD Billion) |
    77. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY APPLICATION, 2025-2035 (USD Billion) |
    78. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY APPLICATION, 2025-2035 (USD Billion) |
    79. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY APPLICATION, 2025-2035 (USD Billion) |
    80. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY APPLICATION, 2025-2035 (USD Billion) |
    81. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY APPLICATION, 2025-2035 (USD Billion) |
    82. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY APPLICATION, 2025-2035 (USD Billion) |
    83. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY APPLICATION, 2025-2035 (USD Billion) |
    84. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY APPLICATION, 2025-2035 (USD Billion) |
    85. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY APPLICATION, 2025-2035 (USD Billion) |
    86. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY APPLICATION, 2025-2035 (USD Billion) |
    87. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY APPLICATION, 2025-2035 (USD Billion) |
    88. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY APPLICATION, 2025-2035 (USD Billion) |
    89. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY APPLICATION, 2025-2035 (USD Billion) |
    90. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY APPLICATION, 2025-2035 (USD Billion) |
    91. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY APPLICATION, 2025-2035 (USD Billion) |
    92. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY APPLICATION, 2025-2035 (USD Billion) |
    93. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY APPLICATION, 2025-2035 (USD Billion) |
    94. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY APPLICATION, 2025-2035 (USD Billion) |
    95. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY APPLICATION, 2025-2035 (USD Billion) |
    96. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY APPLICATION, 2025-2035 (USD Billion) |
    97. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY APPLICATION, 2025-2035 (USD Billion) |
    98. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY APPLICATION, 2025-2035 (USD Billion) |
    99. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    100. 7.32 ACQUISITION/PARTNERSHIP | |

Anti Ageing Drugs Market Segmentation

Anti Ageing Drugs Market By Drug Class (USD Billion, 2025-2035)

  • Serums And Supplements
  • Antioxidants And Enzymes
  • Stem Cells
  • Drugs

Anti Ageing Drugs Market By Application (USD Billion, 2025-2035)

  • Skin And Hair
  • Skeletal And Muscles
  • Age Related Disorders
  • Others
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.